Aytu BioScience Inc Stock News

DENVER, CO / ACCESS Newswire / September 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences: MicroCap Rodeo Fall Conference Date: Thursda...

Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q4 2025 Earnings Call September 23, 2025 4:30 PM EDT Company Participants Joshua Disbrow - CEO & Director Ryan J. Selhorn - CFO, Corporate Secretary & Treasurer Conference Call Participants Robert Blum - Lytham Partners, LLC Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Nazibur Rahman - Maxim Group LLC, Research Division Edward Woo - Asc...

Full year fiscal 2025 net revenue of $66.4 million Full year fiscal 2025 net loss of $13.6 million Full year fiscal 2025 adjusted EBITDA1 of $9.2 million $31.0 million cash balance at June 30, 2025 Exclusive agreement in June 2025 to commercialize EXXUA™ (gepirone) extended-release tablets ("EXXUA") is expected to serve as a major growth catalyst; the Company anticipates launching EXXUA in the ...

DENVER, CO / ACCESS Newswire / September 16, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2025 full year and fourth quarter, after the market close on T...

HealthTech CFO with extensive public company experience building organizations for growth and value creation Demonstrated success in raising capital, driving profitability, and scaling operations to $500M revenue while ensuring compliance and strengthening financial integrity Broomfield, CO, September 3, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.

DENVER, CO / ACCESS Newswire / June 25, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced the appointment of Dr. Gerwin Westfield, PhD as Senior Vice President of Scientific Affairs, effective June 30, 2025...

Term loan maturity extended by 12 months to June 2029 Principal balance on term loan expanded to $13.0 million from $11.1 million currently Expanded revolving line of credit facility by $1.5 million Expanded facilities allow for added working capital flexibility as commercial launch of EXXUA is anticipated to occur in the fourth calendar quarter of 2025 DENVER, CO / ACCESS Newswire / June 23, 2...

Gross proceeds from offering total $16.6 million. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepine Capital Management, with participation from Aytu management and new institutional shareholders.